Baidu
map

Stem Cell Rep:干细胞能逆转糖尿病吗?

2019-02-01 佚名 中国生物技术网

对于糖尿病患者来说,通过恰当的护理方法可以控制住病情,但目前还没有彻底治愈的方法。一些科学家认为,将干细胞转化为分泌胰岛素的细胞或许能带来治愈糖尿病的希望。

对于糖尿病患者来说,通过恰当的护理方法可以控制住病情,但目前还没有彻底治愈的方法。一些科学家认为,将干细胞转化为分泌胰岛素的细胞或许能带来治愈糖尿病的希望。



近日,美国华盛顿大学(UW)医学院在《Stem Cell Reports》上发表的一项研究,对于未来糖尿病的治疗具有重要意义。



在过去的研究中,研究人员成功将干细胞转化为能产生胰岛素的β细胞。然而,在早期的尝试中这种方法出现了问题,主要是因为很难调节新β细胞产生的的胰岛素水平。

UW的研究团队通过调整细胞发育的方式,已经产生了对血液中葡萄糖水平更敏感的β细胞。

研究人员发现,当他们将这些新细胞移植到无法产生胰岛素的小鼠体内时,这些细胞在几天内就会开始分泌胰岛素。更好的是,这些细胞可以帮助控制小鼠的血糖长达数月。



首席研究员Jeffrey R. Millman博士说:“我们已经能克服这些细胞在以前开发方式中的主要问题。而且,新的胰岛素生成细胞在遇到葡萄糖时反应更快更恰当。这些细胞的行为更像是没有糖尿病人体内的β细胞。”

这种方法对人类有效吗?

随着糖尿病发病率的持续上升,毫无疑问研究人员非常希望找到治疗这种疾病的新方法。

Millman博士是2014年首次将皮肤细胞转化为干细胞研究团队的成员,然后他们又在2016年使用糖尿病患者的皮肤细胞转化为干细胞。

在这两次研究中,研究团队都致力于将干细胞转化为胰岛素生成细胞,但是这些新细胞并不能很好地发挥作用。在某些情况下,它们会产生过多的胰岛素,而在另一些情况下,又无法产生足够的胰岛素。这两种情况对于控制糖尿病都是不利的。

然而,在这项新研究中,新产生的细胞更加可靠。

Millman博士说:“这些新细胞更加敏感,分泌的胰岛素能更好地响应葡萄糖水平。”

这项研究为糖尿病研究者提供了一个令人兴奋的新方向,它能否产生胰岛素并在人体中很好地发挥作用?研究团队表示临床试验是必须的,但首先需要开发一种在人体内安全检测细胞的方法。

如果真能达到这一目标,Millman计划大规模生产这种细胞。他和他的团队在短短几周内就已经产生了超过十亿个β细胞。尽管前面还有很长的路要走,但原则上,这对糖尿病的治疗将是一个重大的促进。

原始出处:
Leonardo Velazco-Cruz, Jiwon Song, Kristina G. Maxwell, et al. Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells. Stem Cell Reports. Jan 2019.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1871125, encodeId=855c18e112593, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 06 18:03:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794676, encodeId=67c91e9467643, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 11 14:03:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961402, encodeId=28a2196140206, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 13 03:03:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482229, encodeId=5bfb148222906, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Sun Feb 03 13:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042224, encodeId=28301042224f7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 02 01:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1871125, encodeId=855c18e112593, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 06 18:03:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794676, encodeId=67c91e9467643, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 11 14:03:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961402, encodeId=28a2196140206, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 13 03:03:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482229, encodeId=5bfb148222906, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Sun Feb 03 13:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042224, encodeId=28301042224f7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 02 01:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1871125, encodeId=855c18e112593, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 06 18:03:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794676, encodeId=67c91e9467643, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 11 14:03:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961402, encodeId=28a2196140206, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 13 03:03:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482229, encodeId=5bfb148222906, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Sun Feb 03 13:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042224, encodeId=28301042224f7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 02 01:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-10-13 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1871125, encodeId=855c18e112593, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 06 18:03:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794676, encodeId=67c91e9467643, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 11 14:03:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961402, encodeId=28a2196140206, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 13 03:03:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482229, encodeId=5bfb148222906, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Sun Feb 03 13:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042224, encodeId=28301042224f7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 02 01:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1871125, encodeId=855c18e112593, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Wed Nov 06 18:03:00 CST 2019, time=2019-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794676, encodeId=67c91e9467643, content=<a href='/topic/show?id=82b416e79f5' target=_blank style='color:#2F92EE;'>#stem cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16779, encryptionId=82b416e79f5, topicName=stem cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Nov 11 14:03:00 CST 2019, time=2019-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961402, encodeId=28a2196140206, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 13 03:03:00 CST 2019, time=2019-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482229, encodeId=5bfb148222906, content=<a href='/topic/show?id=8cc416e78f3' target=_blank style='color:#2F92EE;'>#STEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16778, encryptionId=8cc416e78f3, topicName=STEM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1067833268, createdName=12498bb3m92(暂无昵称), createdTime=Sun Feb 03 13:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042224, encodeId=28301042224f7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Feb 02 01:03:00 CST 2019, time=2019-02-02, status=1, ipAttribution=)]
    2019-02-02 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Cell Stem Cell:首次!刘光慧等团队利用基因编辑获得遗传增强人类血管细胞

干细胞技术在再生医学中具有广阔的应用前景。由干细胞体外诱导分化获得的多种类型细胞移植入病灶部位后,可达到促进病损组织再生、恢复组织器官稳态和功能的目的。然而,干细胞治疗在有效性和安全性方面尚存局限,极大地阻碍了该技术的普及。

Nat Neurosci:哈佛大学揭示“渐冻症”(ALS)的潜在治疗靶标

哈佛大学干细胞科学家领导的研究指出了肌萎缩侧索硬化症(ALS)的一个潜在的新生物标记物和药物靶点,ALS是一种非常难以诊断和治疗的神经疾病。发表在Nature Neuroscience杂志的该研究利用人类运动神经元的干细胞模型揭示了STMN2基因作为潜在的治疗靶点,证明了这种人类干细胞模型方法在药物发现中的价值。

新进展!干细胞药物上市迈出了一大步

近日,国内以药品形式申报的干细胞治疗产品的新药临床试验申请(IND)获得了批准,意味着我国干细胞药物上市迈出了一大步。也就是说,国内患者能够使用上干细胞药物的日子越来越近了。

PNAS:揭示蛋白JAG1在癌症干细胞分化和转移中起关键作用

在一项新的研究中,来自美国莱斯大学和杜克大学的研究人员发现发现一种较小的蛋白--- JAG1---似乎在癌症干细胞如何发生分化和转移中发挥着关键性作用。至关重要的是,他们发现JAG1与在调节细胞命运中起着至关重要作用的Notch信号通路相互作用。相关研究结果发表在2019年1月2日的PNAS期刊上,论文标题为“Toward understanding cancer stem cell hetero

陆佩华院长在2019世界干细胞峰会(WSCS)发表主题演讲

2019年1月22日-25日,2019世界Phacilitate Leaders峰会和世界干细胞峰会(WSCS)在美国佛罗里达州迈阿密隆重举行。国际再生医学基金会(RMF)主办的此次联合峰会是其成立15年来最大规模的会议,来自全世界的超过2000名参会者、150家展商和300位演讲嘉宾齐聚一堂,分享全球细胞及干细胞治疗领域的新技术和新进展,探讨细胞治疗的临床新进展,剖析医疗产业化发展面临的挑战和解

PNAS:一种全新的癫痫治疗方法:干细胞来源的神经元改善患者认知功能

一种全新的癫痫治疗方法:“说服”患者自身细胞变成所需要的神经元。美国大约有340万癫痫症患者,占总人口的1.2%。尽管大多数患者对药物治疗有反应,但是仍有20%-40%患者在尝试多种抗癫痫药物后继续发作。还有一个问题,即使药物能起作用,也可能产生认知和记忆障碍以及抑郁。德州A&M大学医学院分子和细胞医学系教授、再生医学研究所副所长Ashok K. Shetty教授课题组正在展开一项工作,如

Baidu
map
Baidu
map
Baidu
map